drugset / Trial / NCT06188611

A Phase IV Study of Huazhi Rougan Granule

NCT06188611

Phase 4 Completed 282 enrolled Shandong New Time Pharmaceutical Co., LTD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Placebo control, Randomized, Double-blind, Multicenter Phase IV study to investigate the efficacy and safety of Huazhi Rougan granule in the treatment of non-alcoholic simple fatty liver (damp-heat obstruction syndrome: Shi-Re-Zhong-Zu Zheng)

Timeline

Start
2017-05-18
Primary completion
2018-11-08
Completion
2018-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Huazhi Rougan Granule Unknown Oral

Indications

No indication recorded.